Writing Biology: DNA Synthesis & Genome Editing

Writing and editing DNA is still the rate limiter on everything built downstream, and the constraint is not one number. Buyers trade cost per base against length, error rate, turnaround, and format, which is why an oligo pool and a multi-kilobase construct are effectively different products. This subset covers synthesis and assembly (phosphoramidite and enzymatic, outsourced and benchtop), error correction and sequence design, and the editing toolkit of CRISPR variants, base and prime editing, and large-fragment insertion.

Protein & Strain Engineering

Designing a protein is no longer the hard part. Generative models now produce credible candidates faster than labs can test them, and the constraint has moved to what happens next: whether a design expresses solubly, folds as intended, holds up under process conditions, and can be produced at titer in a real host. There is still no reliable predictive model for soluble expression, and structure-prediction confidence does not tell you whether a design will work at the bench. This subset covers both halves of that problem, from computational design and directed evolution through enzyme engineering, expression systems, and strain and cell line development across microbial, yeast, and mammalian hosts.

Reading Biology: Genomics to Multi-Omics

Sequencing solved reading DNA, but the layers where the actionable signal usually sits are harder. Proteins cannot be amplified, so their roughly seven orders of magnitude of abundance land directly on the instrument, which is why proteomics still trails genomics on depth, throughput, and cost per sample. This subset covers the tools closing that gap across transcriptomics, proteomics, and metabolomics, the spatial and single-cell platforms adding resolution to all three, the sample prep and enrichment that gate every one of them, and the integration layer that makes the results usable together.

Biomanufacturing & Scale-Up

Most bio-based products fail on economics rather than biology. Media and feedstock dominate the cost stack, facility depreciation follows, and titer is the variable that moves everything because media and utility costs are fixed per liter of broth whether or not there is much product in it. Meanwhile only around twenty facilities worldwide operate tanks above 100,000 liters, and a new commercial plant runs into the hundreds of millions. This subset covers what it takes to close that gap: fermentation and bioprocess engineering, alternative feedstocks, downstream processing and recovery, continuous and intensified processing, CDMO capacity and brownfield conversion, and the techno-economic analysis that determines whether a first plant gets financed at all.

Lab Infrastructure: Instruments, Reagents & Informatics

The constraint on lab throughput is less often the instrument than what it takes to connect it to everything else. Proprietary drivers, vendor-specific data formats, and uneven standards adoption make multivendor systems expensive to build and maintain, which is why capable hardware frequently sits underused. This subset covers that physical and informational layer: liquid handling and lab robotics, reagents and consumables and their supply economics, LIMS, ELN, and scheduling software, and the interoperability standards that let mixed-vendor labs actually run. It also covers the buy-versus-build alternative, from CROs to cloud and remote lab services.

Writing Biology: DNA Synthesis & Genome Editing

Writing and editing DNA is still the rate limiter on everything built downstream, and the constraint is not one number. Buyers trade cost per base against length, error rate, turnaround, and format, which is why an oligo pool and a multi-kilobase construct are effectively different products. This subset covers synthesis and assembly (phosphoramidite and enzymatic, outsourced and benchtop), error correction and sequence design, and the editing toolkit of CRISPR variants, base and prime editing, and large-fragment insertion.

Protein & Strain Engineering

Designing a protein is no longer the hard part. Generative models now produce credible candidates faster than labs can test them, and the constraint has moved to what happens next: whether a design expresses solubly, folds as intended, holds up under process conditions, and can be produced at titer in a real host. There is still no reliable predictive model for soluble expression, and structure-prediction confidence does not tell you whether a design will work at the bench. This subset covers both halves of that problem, from computational design and directed evolution through enzyme engineering, expression systems, and strain and cell line development across microbial, yeast, and mammalian hosts.

Reading Biology: Genomics to Multi-Omics

Sequencing solved reading DNA, but the layers where the actionable signal usually sits are harder. Proteins cannot be amplified, so their roughly seven orders of magnitude of abundance land directly on the instrument, which is why proteomics still trails genomics on depth, throughput, and cost per sample. This subset covers the tools closing that gap across transcriptomics, proteomics, and metabolomics, the spatial and single-cell platforms adding resolution to all three, the sample prep and enrichment that gate every one of them, and the integration layer that makes the results usable together.

Biomanufacturing & Scale-Up

Most bio-based products fail on economics rather than biology. Media and feedstock dominate the cost stack, facility depreciation follows, and titer is the variable that moves everything because media and utility costs are fixed per liter of broth whether or not there is much product in it. Meanwhile only around twenty facilities worldwide operate tanks above 100,000 liters, and a new commercial plant runs into the hundreds of millions. This subset covers what it takes to close that gap: fermentation and bioprocess engineering, alternative feedstocks, downstream processing and recovery, continuous and intensified processing, CDMO capacity and brownfield conversion, and the techno-economic analysis that determines whether a first plant gets financed at all.

Lab Infrastructure: Instruments, Reagents & Informatics

The constraint on lab throughput is less often the instrument than what it takes to connect it to everything else. Proprietary drivers, vendor-specific data formats, and uneven standards adoption make multivendor systems expensive to build and maintain, which is why capable hardware frequently sits underused. This subset covers that physical and informational layer: liquid handling and lab robotics, reagents and consumables and their supply economics, LIMS, ELN, and scheduling software, and the interoperability standards that let mixed-vendor labs actually run. It also covers the buy-versus-build alternative, from CROs to cloud and remote lab services.

Writing Biology: DNA Synthesis & Genome Editing

Writing and editing DNA is still the rate limiter on everything built downstream, and the constraint is not one number. Buyers trade cost per base against length, error rate, turnaround, and format, which is why an oligo pool and a multi-kilobase construct are effectively different products. This subset covers synthesis and assembly (phosphoramidite and enzymatic, outsourced and benchtop), error correction and sequence design, and the editing toolkit of CRISPR variants, base and prime editing, and large-fragment insertion.

Reading Biology: Genomics to Multi-Omics

Sequencing solved reading DNA, but the layers where the actionable signal usually sits are harder. Proteins cannot be amplified, so their roughly seven orders of magnitude of abundance land directly on the instrument, which is why proteomics still trails genomics on depth, throughput, and cost per sample. This subset covers the tools closing that gap across transcriptomics, proteomics, and metabolomics, the spatial and single-cell platforms adding resolution to all three, the sample prep and enrichment that gate every one of them, and the integration layer that makes the results usable together.

Lab Infrastructure: Instruments, Reagents & Informatics

The constraint on lab throughput is less often the instrument than what it takes to connect it to everything else. Proprietary drivers, vendor-specific data formats, and uneven standards adoption make multivendor systems expensive to build and maintain, which is why capable hardware frequently sits underused. This subset covers that physical and informational layer: liquid handling and lab robotics, reagents and consumables and their supply economics, LIMS, ELN, and scheduling software, and the interoperability standards that let mixed-vendor labs actually run. It also covers the buy-versus-build alternative, from CROs to cloud and remote lab services.

Protein & Strain Engineering

Designing a protein is no longer the hard part. Generative models now produce credible candidates faster than labs can test them, and the constraint has moved to what happens next: whether a design expresses solubly, folds as intended, holds up under process conditions, and can be produced at titer in a real host. There is still no reliable predictive model for soluble expression, and structure-prediction confidence does not tell you whether a design will work at the bench. This subset covers both halves of that problem, from computational design and directed evolution through enzyme engineering, expression systems, and strain and cell line development across microbial, yeast, and mammalian hosts.

Biomanufacturing & Scale-Up

Most bio-based products fail on economics rather than biology. Media and feedstock dominate the cost stack, facility depreciation follows, and titer is the variable that moves everything because media and utility costs are fixed per liter of broth whether or not there is much product in it. Meanwhile only around twenty facilities worldwide operate tanks above 100,000 liters, and a new commercial plant runs into the hundreds of millions. This subset covers what it takes to close that gap: fermentation and bioprocess engineering, alternative feedstocks, downstream processing and recovery, continuous and intensified processing, CDMO capacity and brownfield conversion, and the techno-economic analysis that determines whether a first plant gets financed at all.